Frailty Considerations and Fall Risk Rapid weight loss and decreased food intake in frail elderly patients can increase fall risk, orthostatic hypotension, and sarcopenia
Study patients who achieved maximum tolerated dose of 10 mg or 15 mg tirzepatide weekly by week 36 were then randomized 1:1 to continue tirzepatide or receive matching placebo subq injections for 52 weeks
Schedule a consultation with TransformYou today and see how our personalized tirzepatide treatments can help you achieve lasting weight loss and better blood sugar control
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) A substudy of the phase 2 obesity trial specifically examined GLP3s effects on liver fat in participants with metabolic dysfunction-associated steatotic liver disease[12]: Mean relative liver fat reduction of 82.4% with 12 mg dose at 24 weeks 86% of participants on 12 mg achieved normal liver fat levels (below 5%) at 24 weeks Liver fat reductions significantly correlated with improvements in insulin sensitivity, abdominal fat, and metabolic parameters Dose-dependent improvements observed across all dose groups compared to placebo These results suggest potential therapeutic applications beyond weight management, addressing hepatic complications of obesity and metabolic syndrome
En el caso de las mujeres los resultados son an mejores, ya que se estudi a 170 mujeres de 35 aos con sndrome de ovario poliqustico, y se encontr que quienes tomaron suplementos de L-Carnitina tuvieron tasas de ovulacin 64,4% ms altas y tejido endometrial ms grueso que las del grupo de placebo
